Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00884845 · ClinicalTrials.gov registry record · Phase 1
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
A Phase 1 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00884845 is a Phase 1 study that has completed, run by PharmaMar. The registered enrollment target is 35 participants.
The verdict
NCT00884845, a Phase 1 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.
Interventions
- DRUG Erlotinib
- DRUG PM02734 and erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00884845
The ClinicalTrials.gov registry entry for NCT00884845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00884845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00884845 about?
NCT00884845 is a clinical study titled "Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors". Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotini...
What is the current status of trial NCT00884845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2009-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00884845?
The interventions under investigation include: Erlotinib (DRUG), PM02734 and erlotinib (DRUG).
Who is sponsoring clinical trial NCT00884845?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.